title: Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.
abstract: The objectives of this study were to evaluate the reliability of Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis disease activity index (BASDAI) in Chinese ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA) patients. 664 AS patients by the revised New York criteria for AS and 252 USpA patients by the European Spondyloarthropathy Study Group criteria were enrolled. BASDAI and BASFI questionnaires were translated into Chinese. Participants were required to fill in BASFI and BASDAI questionnaires again after 24 h. Moreover, BASDAI and BASFI were compared in AS patients receiving Enbrel or infliximab before and after treatment. For AS group, BASDAI ICC: 0.9502 (95% CI: 0.9330-0.9502, α=0.9702), BASFI ICC: 0.9587 (95% CI: 0.9521-0.9645, α=0.9789). For USpA group, BASDAI ICC: 0.9530 (95% CI: 0.9402-0.9632, α=0.9760), BASFI ICC: 0.9900 (95% CI: 0.9871-0.9922, α=0.9950). In the AS group, disease duration, occipital wall distance, modified Schober test, chest expansion, ESR, and CRP showed significant correlation with BASDAI and BASFI (all P<0.01). In the USpA group, onset age, ESR, and CRP were significantly correlated with BASDAI (all P<0.05), while modified Schober test, ESR, and CRP were significantly associated with BASFI (all P<0.05). The change in BASDAI and BASFI via Enbrel or infliximab treatment showed a significant positive correlation (P<0.01). The two instruments have good reliability and reference value regarding the evaluation of patient's condition and anti-TNF-α treatment response.
authors.affiliation: Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Tianhe Road No 600, 510630, Guangzhou, China.
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Lin
authors.forename: Jieruo
authors.initials: J
authors.lastname: Gu
authors.forename: Peigen
authors.initials: P
authors.lastname: He
authors.forename: Jiesheng
authors.initials: J
authors.lastname: Gao
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Zuo
authors.forename: Zhizhong
authors.initials: Z
authors.lastname: Ye
authors.forename: Fengmin
authors.initials: F
authors.lastname: Shao
authors.forename: Feng
authors.initials: F
authors.lastname: Zhan
authors.forename: Jinying
authors.initials: J
authors.lastname: Lin
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Yanlin
authors.initials: Y
authors.lastname: Wei
authors.forename: Manlong
authors.initials: M
authors.lastname: Xu
authors.forename: Zetao
authors.initials: Z
authors.lastname: Liao
authors.forename: Qu
authors.initials: Q
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D044466:Asian People; D004185:Disability Evaluation; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D025242:Spondylarthropathies / Q000175:diagnosis* / Q000188:drug therapy; D013167:Spondylitis, Ankylosing / Q000175:diagnosis* / Q000188:drug therapy; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept